Assessing brain changes during and after serotonergic psychedelics
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
This study is testing how psychedelics like psilocybin and LSD affect brain activity and thinking in people with and without mental health issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 2 sites (Hamden, Connecticut and 1 other locations) |
| Trial ID | NCT06624137 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how serotonergic psychedelics, such as psilocybin and LSD, affect brain information processing in individuals with and without mental illnesses. Participants will be involved in various assessments before, during, and after the administration of these psychedelics through clinical protocols at Yale University. The study will explore changes in brain activity, perception, and belief systems, as well as the potential long-lasting effects of these substances. By understanding these mechanisms, the research seeks to enhance therapeutic outcomes while minimizing adverse effects.
Who should consider this trial
Good fit: Ideal candidates include individuals participating in approved clinical protocols at Yale University that involve serotonergic psychedelics and who do not have pre-existing psychotic symptoms.
Not a fit: Patients with current intoxication, significant cognitive impairments, or a history of seizures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved therapeutic strategies for mental health conditions by harnessing the beneficial effects of psychedelics.
How similar studies have performed: Other studies have shown promising results with serotonergic psychedelics in treating mental health conditions, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics * Absence of pre-existing psychotic symptoms Exclusion Criteria: * Current intoxication based on self-report * Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report * History of seizures based on self-report * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)
Where this trial is running
Hamden, Connecticut and 1 other locations
- Connecticut Mental Health Center — Hamden, Connecticut, United States (Recruiting)
- West Haven VA Medical Center — West Haven, Connecticut, United States (Recruiting)
Study contacts
- Principal investigator: Albert R Powers, MD, PhD — Yale University
- Study coordinator: Maximillian S Greenwald, BA
- Email: maximillian.greenwald@yale.edu
- Phone: 4254959793
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.